KRAS drug developers are advancing to the next generation of targeted therapies for lung cancer, according to early-cut data highlighted in a new report from San Diego. The coverage points to improvements in the newest attempts versus earlier efforts, with KRAS mutations driving a large share of cancer incidence. For companies, the message is that the field is moving from first-wave efficacy limits toward more promising profiles, setting up what will likely be a data-dense period for ongoing registrational and expansion studies. Clinicians are watching closely for any signal of stronger durability or broader activity across mutation subtypes. The report frames the competitive race as companies refine mechanisms and dosing strategies to address resistance patterns that have constrained prior KRAS programs in clinic.